Considering onset of depression forms a correlation to target protein signal suppression of mammalian rapamycin, ketamine has the potential to indirectly promote brain-derived neurotrophic factor synthesis and release and rapidly activate target protein signaling of mammalian rapamycin by blocking NMDA receptors. This evidence concerns the gene BDNF and major depressive disorder.